Photo credits
Why Propranolol Matters in Psychiatry
Propranolol is a cardiology drug that psychiatry adopted and never gave back. It is a non-selective beta blocker (it antagonizes both β1 receptors, in the heart, and β2 receptors, in the lungs, peripheral vasculature, and skeletal muscle), and it happens to be highly lipophilic, so it crosses the blood-brain barrier readily. Those two facts, non-selectivity and CNS penetration, are the entire reason it earns a place in the psychiatric formulary.
It does three things for us that few other cheap, well-understood drugs do. First, it is the classic "stage fright" drug: a single 10 to 40 mg dose an hour before a performance flattens the somatic cascade of performance anxiety (the pounding heart, the shaking hands, the quavering voice, the sweating), without sedation and without any risk of dependence. Second, it is a mainstay for medication-induced tremor, especially the fine postural tremor of lithium and valproate. Third, it is an evidence-based, traditionally first-line treatment for antipsychotic-induced akathisia, one of the most distressing and dangerous adverse effects we produce.
None of this is glamorous, and propranolol has no marketing behind it: it went generic decades ago. But it is a tool you reach for weekly: the musician terrified of an audition, the patient whose lithium tremor is ruining their handwriting, the person on aripiprazole who cannot sit still and whose suicide risk is climbing unnoticed because of it.
Propranolol is a precise, low-cost instrument for the autonomic and motor symptoms that psychiatric illness and psychiatric drugs generate, provided you respect two hard limits (reactive airway disease and abrupt discontinuation) and remember that it treats the body's alarm signals, not the fear or the psychosis underneath them.
Part 1: Indications
Propranolol has no FDA psychiatric indication. The immediate-release tablets are FDA-approved for hypertension, angina, rate control in atrial fibrillation, reducing cardiovascular mortality after myocardial infarction, migraine prophylaxis, familial or hereditary essential tremor, hypertrophic subaortic stenosis, and (as an adjunct to alpha blockade) pheochromocytoma. Every use below is off-label but grounded in decades of clinical practice and, for akathisia, in randomized trials.
The Core Psychiatric Uses
Performance ("situational") anxiety
This is propranolol's best-known psychiatric use. The target is the performance-only subtype of social anxiety disorder: the person who is fine socially but falls apart when they must perform or be evaluated, such as public speaking, musical auditions, oral exams, a surgeon's first solo case, or a nervous best-man toast. Propranolol taken before the event blunts the autonomic surge that otherwise feeds a vicious cycle (the patient notices their own racing heart and shaking hands, interprets it as impending catastrophe, and spirals). Multiple studies from the 1970s and 1980s showed benefit in non-clinical performers: musicians, test-takers, dental-phobics, surgeons.
Propranolol works for performance social anxiety, not for generalized social anxiety disorder. If your patient is anxious across most social situations, not just when performing, propranolol is the wrong drug; they need an SSRI/SNRI and likely therapy. Ask the discriminating question: "Are you anxious just before and during the performance, or all the time around people?"
Despite how popular and intuitively sensible this strategy is, the RCT evidence in clinically diagnosed SAD is surprisingly thin. Much of the support is from small, dated studies in non-clinical performers, and the head-to-head beta-blocker trials in clinical SAD used atenolol, which did not work. Propranolol is still a reasonable, low-risk, non-addictive PRN for discrete performance situations, and clinical experience strongly favors it, but do not oversell it as rigorously proven.
Medication-induced tremor
Lithium's fine, high-frequency postural tremor is the paradigm case; valproate produces a similar tremor. This is an enhanced physiologic tremor mediated peripherally through β2 receptors in skeletal muscle, which is exactly why a non-selective beta blocker like propranolol works and why β1-selective agents are less reliable for it. Propranolol is a standard second-line move once dose reduction and caffeine reduction have been tried.
Antipsychotic-induced akathisia
Propranolol is a traditional first-line treatment, and akathisia is not a nuisance side effect; it is an emergency of quality of life. Patients describe an unbearable inner restlessness, an inability to stay still, and it demonstrably raises suicide risk.
If a patient on an antipsychotic walks in place or repeatedly gets up for no reason while you're talking, it's almost always akathisia. It is chronically underdiagnosed and misread as anxiety or agitation, which leads to the disastrous move of increasing the antipsychotic.
Two caveats. First, propranolol's efficacy for akathisia, while real, is modest: a 2024 network meta-analysis of 15 double-blind RCTs put it behind mirtazapine, biperiden, vitamin B6, trazodone and mianserin (see Part 8). It did separate from placebo, where clonazepam and valproate did not; its first-line status is as much tradition as demonstrated superiority. Second, it requires slow titration, which is a problem for an urgent, suicide-associated symptom, hence the common practice of bridging with a benzodiazepine (see Part 3).
PTSD hyperarousal
For the hypervigilance and physiologic "activation" of PTSD, a beta blocker (or an alpha-2 agonist like clonidine) can be a reasonable symptomatic option, and it carries none of the stigma some patients attach to "psychiatric" medications, a real advantage in engaging treatment-naive trauma patients.
Distinguish two entirely separate PTSD claims. Using propranolol to treat ongoing hyperarousal is a reasonable symptomatic strategy. Using it immediately after a trauma to prevent PTSD from developing (the idea of blunting consolidation of the traumatic memory) was a beautiful theory that failed in placebo-controlled trials: early open-label promise did not survive randomization. Do not deploy propranolol as post-trauma prophylaxis and expect it to prevent PTSD.
Where Propranolol Does Not Belong
- Generalized social anxiety disorder: ineffective; use an SSRI/SNRI.
- Panic disorder as monotherapy: mixed-to-poor evidence. (There is a narrow signal for augmentation: pindolol 2.5 mg TID added to fluoxetine beat placebo in one small trial in treatment-resistant panic, though the effect is usually attributed to 5-HT1A autoreceptor blockade rather than to beta blockade, and it remains a niche rather than a mainstream indication.)
- Post-trauma PTSD prevention: negative RCTs.
Part 2: Before You Start
Propranolol needs far less workup than lithium; the assessment is little more than a cardiopulmonary history plus a pulse.
"Do you have asthma, COPD, or any wheezing/reactive airway problem?" Because propranolol blocks β2 receptors, it can trigger bronchospasm. This is the most important screening question and, in the psychiatric setting, the one most easily forgotten. (See Contraindications, Part 7.)
The Rest of the Screen
- Cardiac history: known bradycardia, AV block, sick sinus syndrome, decompensated heart failure, or symptomatic hypotension. Ask about syncope and dizziness.
- Diabetes: propranolol can mask the adrenergic warning signs of hypoglycemia (tachycardia, tremor); an insulin-treated diabetic may lose their early hypoglycemia cue. Not an absolute bar, but counsel and prefer alternatives where possible.
- Baseline pulse: check it. A resting heart rate already in the 50s changes the calculus.
When to Get an ECG
Routine baseline ECG is not required for the typical psychiatric patient starting low-dose propranolol. Reserve it for patients with pre-existing cardiac disease, or for new dizziness/syncope on treatment, for example a patient on lithium who develops lightheadedness after propranolol is added.
Routine blood pressure monitoring is likewise unnecessary in otherwise healthy young psychiatric patients; it matters most in the elderly and in anyone on other rate- or pressure-lowering drugs.
Part 3: How to Start and Dose
Older adultsFDA labelIn general, dose selection should be cautious, usually starting at the low end of the range (Inderal LA label).In practiceStart low, go slow.
Switching to Inderal LAFDA labelShould not be considered a simple mg-for-mg substitute for tablets. Lower blood levels. Retitration may be needed.In practiceOnce the dose is stable, consolidate to one morning dose: Inderal LA 60 mg every morning, or the equivalent.
StoppingFDA labelIf stopping, taper over a few weeks (Inderal LA, angina) or several weeks (tablets). Migraine: may be advisable; Inderal LA by age, comorbidity, dose.In practiceTaper a standing dose gradually over at least a few weeks. Do not stop it cold.
There are two dosing logics: PRN (performance anxiety) and standing dose (tremor, akathisia, hyperarousal).
Formulation
- Immediate-release propranolol for PRN performance dosing and for initial titration of standing-dose indications. It's cheap and flexible.
- Long-acting propranolol (Inderal LA) once a stable daily dose is established, to consolidate into a single morning dose and improve adherence, especially useful for maintenance akathisia and lithium tremor.
Performance Anxiety: PRN Dosing
- 10 to 40 mg taken 30 to 60 minutes before the anxiety-provoking event. A common practical range is 20 to 40 mg one hour prior.
- Test it first on a low-stakes occasion, never for the first time on the day that matters, both to confirm efficacy and to make sure the patient doesn't feel unpleasantly flat, lightheaded, or bradycardic.
- The effect is on the autonomic/somatic layer: it quiets the racing heart, the tremor, and the sweating. It does not directly touch the cognitive dread, but in many performers, killing the physical feedback loop is enough to break the spiral.
- No standing dose, no taper concern with occasional PRN use.
The dose is titrated to the situation, not to a heart-rate target. A 20 mg dose that steadies a violinist's bow arm is a success even if their pulse barely moves. Start most patients at 10 to 20 mg for a trial, move to 40 mg if the lower dose is insufficient and well tolerated.
Lithium/Valproate Tremor: Standing Dose
- Propranolol 20 mg BID to TID, or
- Propranolol LA 60 mg every morning.
- Titrate to effect; the tremor typically responds at modest doses. First, though, take the obvious upstream steps: lower the offending drug's dose if feasible, and cut caffeine.
Antipsychotic-Induced Akathisia: Standing Dose, Titrated to Pulse
- Start 20 mg two to three times daily (immediate-release).
- Titrate up by response and pulse. Teach the patient to check their pulse before each dose and skip it if the heart rate is below 60 bpm. This single instruction is your outpatient safety net against bradycardia.
- The controlled trials used 20 to 80 mg/day, and most responders settle between 20 and 120 mg/day. There is little rationale for pushing past that range for akathisia.
- Once you've found the effective dose, consolidate to Inderal LA 60 mg QAM (or the equivalent) for convenience.
Akathisia is urgent and raises suicide risk, but propranolol must be started low and titrated slowly. Bridge with a benzodiazepine that acts immediately, for example clonazepam 0.5 mg BID standing plus 0.5 mg q6h PRN, to relieve the patient now while propranolol climbs to an effective dose over days. And don't forget the definitive move when feasible: reduce or switch the offending antipsychotic.
Part 4: Monitoring
Propranolol demands nothing like lithium's lab schedule. The monitoring is clinical and cardiac.
| What | When |
|---|---|
| Resting pulse | Baseline, and patient self-checks before each dose during titration (skip if <60 bpm) |
| Blood pressure / orthostatics | In the elderly and in anyone on other BP-lowering drugs; not routine in healthy young patients |
| ECG | Only with pre-existing cardiac disease, or new dizziness/syncope on treatment |
| Bronchospasm / wheeze | Ask at follow-up, especially early and in anyone with borderline respiratory history |
| Mood | Screen for emergent low mood/fatigue, particularly on standing doses (see Part 5) |
| Glucose awareness | In treated diabetics: counsel that hypoglycemia symptoms may be blunted |
No routine blood tests. The whole safety model is: watch the heart rate, watch the lungs, and don't stop it abruptly.
Part 5: Side Effects and How to Manage Them
Most patients tolerate propranolol well, and most adverse effects are direct, predictable extensions of beta blockade: dose-related and reversible. The cardiovascular ones are the primary concern.
Cardiovascular
- Bradycardia. The dose-limiting effect. Manage with the pulse-check-before-each-dose rule and by holding/lowering the dose if the resting rate drifts below approximately 55 to 60 bpm.
- Hypotension / orthostasis. Most relevant in the elderly and in patients on other antihypertensives. Counsel the classic anti-fall maneuvers: sit on the edge of the bed for a minute before standing; hold onto furniture for a minute before walking.
Respiratory
- Bronchospasm from β2 blockade: the reason propranolol is contraindicated/hazardous in asthma and reactive airway disease. In a patient without lung disease this is rarely an issue, but any new wheeze, cough, or exertional breathlessness deserves attention.
CNS / Mood
- Fatigue is common and expected; it reduces exercise tolerance. Warn athletes and physically active patients specifically.
- Depression is the debated-but-real historical concern. Lipophilic beta blockers that penetrate the CNS (propranolol, metoprolol) have been associated with higher depression rates than the hydrophilic, poorly-penetrating atenolol: in one large study of hypertensive elderly, roughly 13.4% vs 10.2 to 10.5%. The association is modest, and it derives from hypertensive populations on chronic daily dosing; whether the same risk applies to low-dose or PRN psychiatric use is unknown. Still, be cautious in a patient who is already depressed, and if a hypertensive-range beta blocker is unavoidable in someone with depression, atenolol is the safer choice.
If you must give a beta blocker to a depressed hypertensive patient, reach for atenolol (hydrophilic, low CNS penetration), not propranolol. Within psychiatry, the depression signal is a reason to watch mood, not necessarily to withhold a one-off performance dose.
Other
- Sexual dysfunction is reported (as with beta blockers generally).
- Masked hypoglycemia in insulin-treated diabetics: propranolol blunts the adrenergic warning signs (tremor, tachycardia). Sweating (a cholinergic sign) is generally preserved, but counsel patients to rely on glucose checks rather than symptoms.
Part 6: Overdose and Toxicity
Unlike its use in psychiatry, where it is a gentle adjunct, propranolol in overdose is dangerous, and considerably less forgiving than most of the drugs on the psychiatric shelf. This matters when you are prescribing to patients who may be at risk of self-harm.
The Clinical Picture in Overdose
- Bradycardia and hypotension, potentially profound.
- Bronchospasm.
- CNS effects: because propranolol is lipophilic and crosses into the brain, overdose can produce seizures, delirium, and coma, sometimes out of proportion to the cardiovascular findings.
- Conduction disturbance and, in severe cases, cardiovascular collapse.
Supportive care, IV fluids, atropine for bradycardia; glucagon is the classic beta-blocker-overdose antidote; high-dose insulin/euglycemia therapy and vasopressors for refractory cases. This is toxicology/ED territory: the psychiatric point is to anticipate the risk, not to manage the overdose yourself.
For a patient at meaningful self-harm risk (say, someone with akathisia-driven suicidality or PTSD), mind the quantity you dispense. Propranolol's therapeutic index is narrow relative to, say, an SSRI, and a large supply is a real hazard. Prescribe limited amounts, involve family in holding medication when appropriate, and factor this into the risk calculus.
Part 7: Contraindications and Precautions
Give the first two the most weight: they are where propranolol actually hurts people.
β2 blockade can precipitate bronchospasm. Because propranolol is non-selective, it carries this risk in a way that cardioselective agents do somewhat less (though even β1-selective agents lose selectivity at higher doses and are not truly "safe" in significant asthma). If a patient with reactive airway disease genuinely needs beta blockade, that is a decision to make cautiously and usually with a cardioselective agent, not propranolol. COPD carries the same caution; weigh carefully.
Absolute / Strong Contraindications
- Asthma and reactive airway disease (see above).
- COPD: caution for the same reason.
- Severe bradycardia, high-grade AV block (2nd/3rd degree without pacemaker), and sick sinus syndrome: propranolol will worsen conduction.
- Decompensated heart failure: negative inotropy can tip a decompensating patient over. (Stable, compensated heart failure is a different, cardiology-managed situation.)
- Cardiogenic shock / severe hypotension.
- Severe peripheral vascular disease or Raynaud's phenomenon: not a formal US label contraindication, but a recognized caution on other national labels; unopposed alpha-mediated vasoconstriction from beta-2 blockade can worsen ischemia. Ask about cold, painful, or color-changing extremities before starting.
Cautions
- Depression, particularly in hypertensive patients: see Part 5; favor atenolol if a beta blocker is needed.
- Diabetes on insulin/secretagogues: masks hypoglycemia symptoms.
- The elderly: orthostasis, falls, and cognitive impairment if blood pressure drops too low.
Part 8: Propranolol vs the Alternatives
Propranolol vs Benzodiazepines for Performance Anxiety
This is the comparison that comes up most, and for a discrete performance event propranolol usually wins:
- Propranolol treats the somatic/autonomic symptoms (the racing heart, tremor, sweating, shaky voice) without sedation, without cognitive dulling, and with no risk of dependence or abuse. A musician can play, a speaker can think clearly. That is precisely what you want for a one-time high-stakes performance.
- Benzodiazepines work on the subjective anxiety and can be effective, but they sedate, blunt cognition and fine motor precision, and carry dependence and tolerance risk. A benzodiazepine that steadies the nerves but slows the mind or the fingers is a poor trade for a performer or a surgeon.
For a single, predictable performance event, propranolol is often the superior choice: it removes the physical symptoms without touching the patient's edge or clarity, and there's nothing to become dependent on.
Propranolol vs Other Agents for Akathisia
The 2024 network meta-analysis reshaped the hierarchy:
- Mirtazapine 15 mg/day ranked most effective, in the main analysis and in every subgroup analysis, with sedation and weight gain as its drawbacks.
- Vitamin B6 ranked highly, and the reviewers rated it the best option on risk-benefit grounds (it may also improve mood and lower prolactin). The trials used 600 to 1,200 mg/day for five days or more. Pyridoxine causes a sensory neuropathy, classically at chronic doses above 1,000 mg/day but with case reports below 500 mg/day, so keep the course short.
- Propranolol separated from placebo, but sat behind mirtazapine, biperiden, vitamin B6, trazodone and mianserin. Its liability is the slow titration for an urgent symptom.
- Clonazepam/benzodiazepines: useful chiefly as a rapid bridge while propranolol titrates.
- And always: reduce or switch the causative antipsychotic when clinically possible.
Propranolol remains a reasonable first choice in practice, though its standing rests on familiarity as much as on demonstrated superiority. B6 and low-dose mirtazapine deserve a place in the conversation, and the benzodiazepine bridge solves propranolol's biggest weakness.
Propranolol vs Other Beta Blockers
- vs Atenolol (cardioselective, hydrophilic): atenolol barely enters the brain, so it is favored when you want to avoid CNS effects (lower depression signal) but is less useful for the very psychiatric jobs propranolol does well. For tremor, propranolol's non-selectivity (β2 blockade in skeletal muscle) matters; for anxiety and akathisia, its CNS penetration plausibly matters. Atenolol failed in clinical social anxiety trials where propranolol is used empirically. The trade is real: propranolol's lipophilicity is a feature for psychiatric effect and a liability for depression risk.
- Metoprolol sits in between: lipophilic like propranolol but β1-selective.
- Pindolol (a beta blocker with partial agonist activity) has its own niche: 2.5 mg TID added to fluoxetine showed benefit in treatment-resistant panic in one small trial. The usual explanation is 5-HT1A autoreceptor blockade rather than beta blockade, and milligram for milligram pindolol is a several-fold more potent beta blocker than propranolol.
Lipophilicity buys CNS penetration (good for psychiatric targets, worse for depression risk); non-selectivity buys β2 blockade (good for tremor, bad for airways). Propranolol maximizes both, which is exactly why psychiatry likes it and exactly where its two big cautions come from.
Part 9: Discontinuation: Do Not Stop Abruptly
This deserves real prominence. Chronic beta blockade upregulates beta receptors; abrupt withdrawal unmasks them and produces rebound sympathetic overactivity: rebound tachycardia, rebound hypertension, and, in patients with underlying coronary disease, angina or even myocardial ischemia.
For any patient on a standing daily dose, taper; do not stop cold. The label says to reduce the dose gradually over at least a few weeks when stopping is planned. That wording sits in its angina warning, but the extended-release labels say to avoid abrupt discontinuation even in patients treated only for hypertension, because coronary artery disease is common and may be unrecognized. Occasional PRN performance dosing does not create this dependence and needs no taper; the rebound concern is a standing-dose phenomenon (tremor, akathisia, hyperarousal maintenance regimens).
Counsel every patient on a standing dose: "Don't run out and don't quit suddenly. If you want to stop, we'll step it down over at least a few weeks."
The rebound risk scales with cardiac vulnerability. In a healthy 30-year-old on propranolol for lithium tremor, abrupt cessation is unpleasant; in an older patient with coronary disease, it can be dangerous. Taper accordingly.
Part 10: Special Populations
Pregnancy and Lactation
Weigh with obstetrics. Beta blockers used near term have been associated with neonatal bradycardia, hypoglycemia, and reduced fetal growth (better characterized for chronic maternal hypertension treatment than for intermittent psychiatric PRN use). Propranolol does pass into breast milk but generally in low relative amounts considered compatible with breastfeeding by most references, with monitoring of the infant. For an isolated PRN performance dose the systemic-exposure question is very different from chronic daily dosing: individualize, and coordinate with the obstetrician/pediatrician for standing regimens.
The Elderly
- Greater risk of orthostatic hypotension, falls, and cognitive impairment if blood pressure drops too low. Start low, go slow.
- Reinforce the anti-fall maneuvers (edge-of-bed pause, furniture support).
- Most beta-blocker depression data come from this population; watch mood.
Diabetes
- Masks the adrenergic warning signs of hypoglycemia in insulin-treated patients: the most clinically important special-population caveat. Counsel reliance on glucose monitoring, not symptoms.
Renal / Hepatic Impairment
Propranolol is extensively hepatically metabolized (high first-pass), so hepatic impairment raises levels: start lower and titrate cautiously. Renal impairment is less of a driver for propranolol specifically than for hydrophilic, renally-cleared agents like atenolol, but dose conservatively in significant organ dysfunction.
Part 11: Drug Interactions
- Additive bradycardia and hypotension with other rate- and pressure-lowering agents: the most clinically relevant interaction category. Be especially careful with the non-dihydropyridine calcium channel blockers verapamil and diltiazem, whose combined effect on AV conduction and inotropy with a beta blocker can cause dangerous bradycardia and heart block. Also additive with clonidine, other antihypertensives, and other beta blockers.
- CYP2D6 substrate. Propranolol is metabolized partly by CYP2D6, so strong CYP2D6 inhibitors raise its levels. In psychiatry the standout is fluoxetine (a potent CYP2D6/2C19 inhibitor), which can push propranolol concentrations up, and because of fluoxetine's long half-life, the interaction persists for weeks after fluoxetine is stopped (up to ~6 weeks). Paroxetine and bupropion are also 2D6 inhibitors to keep in mind.
- Check for interactions with any cardiac medications the patient is already taking.
Mechanism
Propranolol is a non-selective beta-adrenergic antagonist, blocking both β1 (cardiac, hence rate and contractility reduction) and β2 (bronchial and vascular smooth muscle, skeletal muscle, hence bronchospasm risk and its efficacy against enhanced physiologic tremor) receptors. It is highly lipophilic, so it penetrates the blood-brain barrier well.
That CNS access is central to what it does in psychiatry. By dampening peripheral sympathetic output, propranolol suppresses the somatic symptoms of anxiety (tachycardia, tremor, sweating) and interrupts the interoceptive feedback loop by which a performer's own racing heart amplifies their fear. Its central penetration plausibly contributes to its effects on akathisia and hyperarousal (and, on the debit side, to its depression signal, which the poorly-penetrating atenolol largely lacks). Propranolol treats the body's alarm, not the fear, the psychosis, or the trauma that set the alarm off.
The Bedside Cheat Sheet
Performance anxiety (PRN)
- 10 to 40 mg, 30 to 60 min before the event (commonly 20 to 40 mg × 1 h prior)
- Trial it first on a low-stakes occasion
- Treats somatic symptoms; no sedation, no dependence. Superior to benzodiazepines for a one-off performance
- Only for performance SAD; useless for generalized SAD
Lithium/valproate tremor (standing)
- Propranolol 20 mg BID to TID or Inderal LA 60 mg QAM
- First optimize: lower the offending drug, cut caffeine
Akathisia (standing, titrate to pulse)
- Start 20 mg BID to TID, up to about 120 mg/day
- Check pulse before each dose; skip if <60 bpm
- Bridge with a benzodiazepine (clonazepam 0.5 mg BID) because titration is slow and akathisia is urgent
- Always consider reducing/switching the antipsychotic. (B6 and low-dose mirtazapine are evidence-based alternatives.)
PTSD hyperarousal (standing)
- Start 10 mg TID to QID. (Does not prevent PTSD post-trauma; that failed in RCTs.)
Hard limits
- Contraindicated in asthma/reactive airway disease (non-selective, so it risks bronchospasm); caution in COPD
- Do not stop a standing dose abruptly: taper over at least a few weeks (label); rebound tachycardia/hypertension/angina
- Avoid/caution: severe bradycardia, high-grade AV block, decompensated heart failure
Don't forget
- Masks hypoglycemia in insulin-treated diabetics
- Dangerous in overdose (bradycardia, hypotension, seizures/coma): limit quantities in at-risk patients
- Fluoxetine (and other 2D6 inhibitors) raise propranolol levels, for weeks after stopping
- Verapamil/diltiazem + propranolol leads to dangerous bradycardia
- Depression signal with lipophilic beta blockers: use atenolol if a beta blocker is needed in a depressed hypertensive
Propranolol will never be the star of a psychiatric regimen. It is an adjunct: a way to quiet the body when the body's alarm system has become the problem, whether that alarm is a performer's pounding heart, a lithium-shaken hand, or the intolerable restlessness of akathisia. Used within its two bright lines (never in reactive airway disease, never stopped abruptly from a standing dose), it is one of the safest, cheapest, and most immediately useful tools we have. It lets the frightened perform, steadies the tremulous, and can pull a patient back from the private torment of akathisia. Reach for it often, prescribe it precisely, and remember what it does and does not treat.